Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Niklas Hedberg"'
Autor:
Denis Lacombe, Ad Schuurman, Jessica Imbert, Jordi Llinares Garcia, Valentina Strammiello, Ansgar Hebborn, Flora Giorgio, Edith Frénoy, Giovanni Tafuri, Niklas Hedberg, Ingvil von Mehren Sæterdal, Anne Willemsen, Chantal Belorgey, C. Favaretti, Zoe Garrett, Daniel Widmer, Anna Lefevre Skjöldebrand, Elena Petelos, François Houÿez, Marcus Guardian
Publikováno v:
International Journal of Technology Assessment in Health Care. 36:191-196
The European Network for Health Technology Assessment (EUnetHTA) organizes an annual Forum with stakeholders to receive feedback on its activities, processes, and outputs produced. The fourth edition of the EUnetHTA Forum brought together representat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b1af376ab8afbf9405b6410ff39242d
https://doi.org/10.1017/s0266462320000185
https://doi.org/10.1017/s0266462320000185
Autor:
Spiros Vamvakas, Caridad Pontes, Guido Rasi, Sonia Garcia, Giovanni Tafuri, Elangovan Gajraj, Frank Pétavy, Inês Lucas, Eva-Maria Zebedin-Brandl, Andrea Molina, Mercè Obach, Anne d'Andon, Niklas Hedberg, Pierluigi Russo, Marco Petschulies, Hannah Bruehl, Steve Estevão, Jane Moseley, Marco Massari, Anja Schiel, Leeza Osipenko, Marc Van de Casteele
Publikováno v:
British Journal of Clinical Pharmacology. 84:1013-1019
Aims The parallel regulatory–health technology assessment scientific advice (PSA) procedure allows manufacturers to receive simultaneous feedback from both EU regulators and health technology assessment (HTA) bodies on development plans for new med
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab737af17a45373d25398987e4346be0
https://doi.org/10.1111/bcp.13524
https://doi.org/10.1111/bcp.13524
Autor:
Jane Moseley, Antje Behring, Frank Pétavy, Mercè Obach, Niklas Hedberg, Guido Rasi, Leeza Osipenko, Arantxa Catalan, Eva‐Maria Zebedin, Pierluigi Russo, Marco Massari, Marc Van de Casteele, Spiros Vamvakas, Elangovan Gajraj, Margherita Pagnini, Giovanni Tafuri
Publikováno v:
British Journal of Clinical Pharmacology
BACKGROUND: In 2010, the European Medicines Agency (EMA) initiated a pilot project on parallel scientific advice with Health Technology Assessment bodies (HTABs) that allows manufacturers to receive simultaneous feedback from both the European Union
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36cf2a1c2295f7f9c367a9b9de384308
https://lirias.kuleuven.be/handle/123456789/669469
https://lirias.kuleuven.be/handle/123456789/669469
Autor:
Björn Wettermark, Thomas Kahan, Tor Olov Mellgren, Martin Neovius, Niklas Hedberg, Brian Godman
Publikováno v:
Health policy (Amsterdam, Netherlands). 94(3)
Objective The Swedish Dental and Pharmaceutical Benefits Agency is re-assessing the value of all drugs included in the reimbursement scheme in order to make the most efficient use of resources. Their recent review of antihypertensive drugs included 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57ef423dc4dc0e68054d30eaa7db289f
https://pubmed.ncbi.nlm.nih.gov/19879009
https://pubmed.ncbi.nlm.nih.gov/19879009
Autor:
Björn Wettermark, Tor-Olov Mellgren, Pia Frisk, Anita Berlin, Niklas Hedberg, Fredrik Granath
Publikováno v:
European journal of clinical pharmacology. 64(12)
Angiotensin receptor blockers (ARBs) offer a new treatment alternative for patients with hypertension and heart failure. Due to comparatively high prices, most guidelines suggest ARBs be restricted to patients intolerant to angiotensin-converting enz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2789a7332f08700a92f1e4810b6b9b35
https://pubmed.ncbi.nlm.nih.gov/18704389
https://pubmed.ncbi.nlm.nih.gov/18704389